First Patient Enrolled in Novel Pediatric Cancer Clinical Trial

LOS ANGELES (May 8, 2020) — Today, a USCCLA physician director has announced her intention to enroll in a clinical trial of no patients for pediatric cancer.

Aneesh Kamal, MD, PhD, director of the Marlan and Thomas Lovell Chair in Pediatric Genetics and Neurodevelopment, expects to enroll in trial participants from six California sites that will offer patients an FDA-approved compound, called VK1, to treat advanced or recurrent pediatric central nervous system tumors.

Pursuing patients from the front lines, Kamal will enroll through a phase III trial, funded by the Advisory Council on Immunologic Disorders, established by the U. S. Food and Drug Administration, which will evaluate the safety of VK1 and the usage of favorable toxic chemicals.

“My name is Aneesh Kamal, PhD, and I am a physician in the Brady Brom Graft and Transplant Program at USC. In 2015, without surgery, I discovered and initiated my controversial study, “Congenital Nervous System Tumors in Children with Coronary Endothelioma”, which 3, 200 patients, devastated and killed. Because I have been diagnosed with Hodgkin lymphoma, I devoted my career to improve the treatment of the affected children, ” said Kamal, the emeritus professor in the UCLA Marciana Anderson Family Center for Cancer Research, the Beth Ann Wexler Professor in the USC Norris Comprehensive Cancer Center, and dean of the USC John A. and Mary Lasker School of Medicine. “Today, I have discovered that the therapy is effective in treating 2/3 of patients with the low-grade brain tumors of the brain stem and brain-;the primary lymphoid tissue affected in adult patients with breast, lung, prostate, pancreatic and prostate cancers. The treatment is successfully immunotherapy precise and robust in blocking tumor cells and their ability to spread. It is a massive advance because the drugs used in this study deliver powerful immune cells and allow the immune system to attack tumor cells while destroying their ability to recruit and produce new, normal human T cells. This can be achieved by using an infusion of Vismodegibiotic (Venomizer) chemotherapy or traditional chemotherapy available in Boehringer’s pharmaceuticals division, ” he said.

VK1 or nivolumab as it is sold are a combination of four powerful inhibitors (MK-7184, 7-Zantac, edgardl, ibrutemine and ruxolitin) that sweep through the target tumor cells, suppressing them to allow for remission. VK1 is regarded as an immune checkpoint for tumor cells because it is found in an immune checkpoint compound specifically developed to target and eradicate leukemia. VK1 is also the first immune-based molecule approved by the FDA to treat acute myeloid leukemia and non-Hodgkin lymphoma. Its approval after nearly two years of clinical testing will ensure every patient will benefit from VK1 treatment for the duration of their illnesses.

Other Posts From "Health":

Related Posts